Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 102 and Erlotinib in Previously Treated Advanced NSCLC
NCT01233687Phase 2Completed
- Sponsor
- Ahmad Tarhini
- Start
- Aug 2011
- Primary completion
- Nov 2014
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of rilotumumab in non-small cell lung cancer (NSCLC), sponsored by Ahmad Tarhini. Started Aug 2011; status: completed.
02
Drugs
rilotumumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01233687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01233687.